OSLO, NOVEMBER 1, 2019.

VACCIBODY AS TO HOST CAPITAL MARKETS DAY IN OSLO ON 12th NOVEMBER 2019.

Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, will host its capital markets day on November 12 and is pleased to invite investors, analysts and press to presentations by the members of the company's executive management team and by Ulrich Granzer, PhD, founder of Granzer Regulatory Consulting & Services. Dr. Granzer has a wide range of experience in all aspects of drug development and regulatory affairs, with particular focus on bringing novel therapies to market.

Venue: Forskningsparken, Gaustadalléen 21, 0349 Oslo. Meeting room Faros.

Date: Tuesday, 12th November 2019

Agenda:

14.00-14.10	Introduction	Michael Engsig
14.10-15.00	Update on the VB N-01 study including the clinical data	Agnete Fredriksen
15.00-15.45	Status of the cancer vaccine field and development of novel immunotherapies	Ulrich Granzer
15.45-16.05	Company update	Michael Engsig
16.05-16.30	Questions & Answers	All
16.30-17.30	Mingling, snacks and drinks	All

Registration: e-mail to Hege Juliane Odd (hjodd@vaccibody.com)

About Vaccibody

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. A phase I/IIa neoantigen clinical trial is ongoing treating patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial or squamous cell carcinoma of head and neck. Vaccibody has a collaboration with Nektar Therapeutics, planning to start testing VB10.NEO in combination with bempegaldesleukin (NKTR-214) in squamous cell carcinoma of head and neck in H2 2019. Vaccibody's other program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human study (phase I/IIa), evaluating the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3) has been finalized and has published positive 12 months data. Vaccibody has started a collaboration with Roche, exploring

VB10.16 in combination with their checkpoint inhibitor atezolizumab (Tecentriq™) in up to 50 patients with advanced or recurrent cervical cancer. First patient is expected to be vaccinated in H1 2020. Further information about the company and its drug development programs and capabilities may be found online at http://www.vaccibody.com

For further information, please contact:

Michael Engsig, CEO
+45 61731509
mengsig@vaccibody.com